TO THE EDITOR
The majority of patients with acute myeloid leukemia (AML) achieve complete remission after induction and consolidation therapy. However, a significant proportion of patients eventually relapse and die from their disease. Early detection of minimal residual disease (MRD) may offer the possibility of implementing salvage therapies prior to overt clinical relapse. It is still not entirely clear, however, how to deal with the molecular relapse therapeutically nor how to monitor it. 1 For technical reasons, MRD monitoring is considered especially for patients who suffer from AML with recurrent genetic abnormalities. Acute promyelocytic leukemia with t(15;17) now differs from other AML subtypes, thanks to an effective and tailored therapeutic approach. Further welldefined leukemias considered for MRD monitoring using the quantitative-PCR method are those with t(8;21), inv(16), or t(16;16), and 11q23 abnormalities.
2-5 Frequent MRD monitoring of patients with these forms of AMLs could help to answer the following important questions: (1) How does the MRD behave between the cycles of chemotherapy in AML? (2) How long is the period between the molecular and hematological relapse? (3) Is it possible to increase the success rate of AML therapy by treating the molecular relapse as opposed to treatment begun at the moment of clear hematological relapse?
In an effort to answer these questions, we have performed a pilot study in nine patients (125 specimens, 14 on average in one patient) with the AML with t(8;21), inv(16), and 11q23 abnormalities. We regularly monitored the fusion transcripts AML1/ETO, CBFb/MYH11, and MLL genes using quantitative real-time polymerase chain reaction (RQ-RT-PCR; the expression of the fusion gene to the expression of the housekeeping gene ABL). The specimens of bone marrow and/or peripheral blood were collected before beginning therapy and later in approximately monthly intervals. Molecular genetic examination was correlated with the results of cytogenetic and morphological studies. Molecular relapse (confirmed by repeated examination) was defined as the reappearance of positivity after a previous negative result or as an at least 10-fold rise in positivity.
The results are shown in Table 1 . In patient no. 1, 2, 3, 5, 6, and 8, we observed isolated molecular relapse of the disease (not accompanied by cytogenetic or morphological abnormalities). It seems that patients who do not achieve stable complete molecular remission have a greater probability of suffering from hematological relapse. We did not observe a spontaneous disappearance of the MRD positivity. Unfortunately, to achieve the so-called complete molecular remission is not a definitive guarantee for long-term hematological remission. These patients can also relapse (patient no. 1, 3, 6, 7, and 8). The time period between the molecular relapse and hematological relapse is extremely variable. For example, in patient no. 5, molecular relapse preceded the hematological relapse by 6 months. However, on the other hand, in patient no. 7, fulminate relapse occurred despite being in molecular remission 1 month earlier.
After analyzing the period observed between the first molecular relapse and the following hematological relapse, in patient no. 1, we decided on chemotherapy of the second molecular relapse because of increasing dynamics of the MRD level. The patient was fully informed about the therapy and a written consent was given. Chemotherapy was later administered for similar reasons in patient no. 3 and 6. We used combinations of cytosine arabinoside (100 mg/m 2 /day) and daunorubicin or mitoxantrone. In patient no. 1 and 3, only a decrease in the level of MRD was observed; molecular remission had not been achieved. The decrease was greater than one order in magnitude and we called it a partial molecular response. In patient no. 6, however, the second complete molecular remission was achieved after only one course of chemotherapy, although dysplastic features in the bone marrow appeared. Unfortunately, 4 months after final chemotherapy, this patient developed a second molecular relapse. Moreover, chemotherapy also appeared ineffective in the treatment of MRD in patient no. 2, in whom there had been a rise in the quantity of MRD after the second and third consolidations with high-dose cytosine arabinoside during the first-line treatment of her disease. To the best of our knowledge, this is the first information about chemotherapy of molecular relapse of AMLs with CBFb/MYH11 and AML1/ETO fusion transcripts.
So far there are many ambiguities concerning the follow-up of the residual disease using quantitative RQ-RT-PCR in the AMLs with recurrent genetic abnormalities. The prognostic impact of the detection of CBFb/MYH11 or AML1/ETO transcripts in complete remission of AML as yet has not been clarified. 6 Studies of small groups with AML1/ETO 5 or CBFb/MYH11 2 AML identified tentative quantitative cutoff levels for good-vs poorrisk patients after consolidation therapy, but did not find an association between pretreatment or preconsolidation fusion Correspondence mRNA levels and outcome. Schnittger et al 6 tried to create the predicting score for prognosis in PML/RARa-positive, AML1/ ETO-positive, or CBFb/MYH11-positive AMLs based on quantification of fusion transcripts. They conclude that patients at high risk for treatment failure can be identified by high levels of fusion gene expression at diagnosis or less than 3 logs of tumor reduction during the first 3-4 months of therapy. This score was created on the basis of the analysis of bone marrow specimens of 349 patients. Yet, only four specimens were obtained in 12 months on average from a single patient.
According to the results of our pilot MRD-monitoring study based on regular and frequent MRD analysis, we can hypothesize about the existence of two patterns of relapse of AML. In the first type, the molecular relapse precedes the hematological relapse in a few months and can be well monitored (patient no. 1, 3, 5, and 6), whereas the second type is the fulminate relapse that is not revealed early enough by molecular methods (patient no. 7). Furthermore, we can also hypothesize that after an administration of chemotherapy for molecular relapse, three patterns of response can be seen: restoration of complete molecular remission, partial molecular response, and nonresponse. Nevertheless, we can speculate whether the treatment of molecular relapse prolongs the life of the patients and whether it improves the quality. However, theoretically, maintenance chemotherapy might have this effect at least on relapse-free survival, as has been described by some authors. 7 An important question, however, not addressed in this study, is whether to change the composition of the consolidation chemotherapy if it is not efficient in the eradication of MRD. The administration of the same substances, though in higher doses, did not lead to the eradication of MRD (patient no. 1, 2, and 3).
This study has so far included only a limited number of patients, but their MRD was monitored very frequently. Therefore, we believe that the results can add further information to the description of variability in clinical and biological behavior of AML. The question of treatment of AML patients in molecular The table shows only some of the 125 results of molecular genetic examinations. PB -peripheral blood, BM -bone marrow, FISH -fluorescent in situ hybridization, ND -not done. The entries in 'bold and underline' are important for marking three patients treated for molecular relapse. The sentence 'Before chemotherapy for molecular relapse' points out the moment when the treatment of molecular relapse was started. 
